Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

GXP-PHARMA SUPPORT A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   4.7% 5.4% 4.9% 7.1% 4.3% 10.2% 17.5% 17.5%   Credit score (0-100)   47 41 43 33 47 24 9 9   Credit rating   BBB BBB BBB BBB BBB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,168 1,000 382 211 361 -263 0.0 0.0   EBITDA   -23.5 24.6 153 -58.4 127 -348 0.0 0.0   EBIT   -23.5 24.6 153 -58.4 127 -348 0.0 0.0   Pre-tax profit (PTP)   422.2 851.7 547.8 -440.2 471.0 -213.4 0.0 0.0   Net earnings   328.4 664.1 425.7 -345.5 367.4 -166.4 0.0 0.0   Pre-tax profit without non-rec. items   422 852 548 -440 471 -213 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   1,428 1,692 1,118 772 1,140 373 -127 -127   Interest-bearing liabilities   1,228 1,687 558 79.6 128 78.4 127 127   Balance sheet total (assets)   2,923 3,976 2,177 1,105 1,481 646 0.0 0.0   Net Debt   -1,431 -1,206 -1,005 -747 -1,143 -480 127 127     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,168 1,000 382 211 361 -263 0.0 0.0   Gross profit growth   -23.0% -14.4% -61.8% -44.7% 70.9% 0.0% 0.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,923 3,976 2,177 1,105 1,481 646 0 0   Balance sheet change%   62.2% 36.0% -45.2% -49.3% 34.0% -56.4% -100.0% 0.0%   Added value   -23.5 24.6 152.9 -58.4 126.7 -347.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 1.0 2.0 -1.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -2.0% 2.5% 40.0% -27.7% 35.1% 132.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   18.4% 25.3% 18.1% -2.4% 36.7% -19.1% 0.0% 0.0%   ROI %   21.3% 29.0% 22.0% -3.2% 44.8% -23.6% 0.0% 0.0%   ROE %   26.0% 42.6% 30.3% -36.6% 38.4% -22.0% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   48.9% 42.6% 51.4% 69.9% 77.0% 57.8% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   6,085.6% -4,907.1% -657.5% 1,278.8% -901.6% 138.1% 0.0% 0.0%   Gearing %   86.0% 99.7% 49.9% 10.3% 11.3% 21.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   1.6% 1.5% 0.7% 125.6% 3.6% 9.8% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   2.0 1.7 2.1 3.3 4.3 2.4 0.0 0.0   Current Ratio   2.0 1.7 2.1 3.3 4.3 2.4 0.0 0.0   Cash and cash equivalent   2,659.5 2,893.0 1,563.1 826.6 1,271.0 558.6 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -963.0 -937.2 -399.0 142.4 -103.4 -104.4 -63.4 -63.4   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -24 25 153 -58 127 -348 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -24 25 153 -58 127 -348 0 0   EBIT / employee   -24 25 153 -58 127 -348 0 0   Net earnings / employee   328 664 426 -346 367 -166 0 0